Literature DB >> 9630325

GVHD: overview on pathophysiology, incidence, clinical and biological features.

T Klingebiel1, P G Schlegel.   

Abstract

Acute and chronic graft-versus-host disease (GVHD) develop in a significant proportion of transplant recipients and still represent one of the major causes of morbidity and mortality after allogeneic BMT. Prevention of GVHD does not only attempt to reduce acute toxicity and morbidity of transplantation but also to ameliorate long term outcome. GVHD is a T-cell mediated disease affecting multiple target organ systems. Recent research has tremendously improved our understanding of the pathophysiology of the disease. These new data are reviewed with main emphasis on their impact for children. The most important task for the future will be to make these new strategies fruitful for clinical application.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9630325

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  12 in total

1.  [Cutaneous graft-versus-host disease].

Authors:  S Karrer
Journal:  Hautarzt       Date:  2003-05       Impact factor: 0.751

2.  CD57+ T cells augment IFN-gamma production in a one-way mixed lymphocyte reaction and their expansion after stem cell transplantation in paediatric patients.

Authors:  Y Koike; S Seki; T Ohkawa; T Kaneko; K Kogawa; S Fujitsuka; H Hiraide; I Sekine
Journal:  Clin Exp Immunol       Date:  2002-10       Impact factor: 4.330

3.  Blood fetal microchimerism in primary biliary cirrhosis.

Authors:  P Invernizzi; C De Andreis; S M Sirchia; P M Battezzati; M Zuin; F Rossella; F Perego; M Bignotto; G Simoni; M Podda
Journal:  Clin Exp Immunol       Date:  2000-12       Impact factor: 4.330

4.  Narrowband ultraviolet B phototherapy ameliorates acute graft-versus-host disease by a mechanism involving in vivo expansion of CD4+CD25+Foxp3+ regulatory T cells.

Authors:  Satoshi Iyama; Kazuyuki Murase; Tsutomu Sato; Akari Hashimoto; Ayumi Tatekoshi; Hiroto Horiguchi; Yusuke Kamihara; Kaoru Ono; Shohei Kikuchi; Kohichi Takada; Yutaka Kawano; Tsuyoshi Hayashi; Koji Miyanishi; Yasushi Sato; Rishu Takimoto; Masayoshi Kobune; Satoru Mori; Junji Kato; Toshiharu Yamashita; Junji Kato
Journal:  Int J Hematol       Date:  2014-02-21       Impact factor: 2.490

5.  Extracorporeal photopheresis affects co-stimulatory molecule expression and interleukin-10 production by dendritic cells in graft-versus-host disease patients.

Authors:  M Di Renzo; P Sbano; G De Aloe; A L Pasqui; P Rubegni; A Ghezzi; A Auteri; M Fimiani
Journal:  Clin Exp Immunol       Date:  2008-03       Impact factor: 4.330

Review 6.  Balance of Th1 and Th17 effector and peripheral regulatory T cells.

Authors:  Jens Lohr; Birgit Knoechel; David Caretto; Abul K Abbas
Journal:  Microbes Infect       Date:  2009-04-17       Impact factor: 2.700

7.  Deficient IFN-gamma expression in umbilical cord blood (UCB) T cells can be rescued by IFN-gamma-mediated increase in NFATc2 expression.

Authors:  Suzanne Kadereit; Gwendolyn R Junge; Thomas Kleen; Margaret M Kozik; Beth A Kaminski; Kathleen Daum-Woods; Pingfu Fu; Magdalena Tary-Lehmann; Mary J Laughlin
Journal:  J Clin Immunol       Date:  2003-11       Impact factor: 8.317

8.  Alterations of hemostatic parameters in the early development of allogeneic hematopoietic stem cell transplantation-related complications.

Authors:  Yue Han; Li Zhu; Aining Sun; Xiaoxu Lu; Luping Hu; Lili Zhou; Yongya Ren; Xiaohui Hu; Xiaojin Wu; Zhaoyue Wang; Changgeng Ruan; Depei Wu
Journal:  Ann Hematol       Date:  2011-06-15       Impact factor: 3.673

9.  Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigen.

Authors:  Birgit Knoechel; Jens Lohr; Estelle Kahn; Jeffrey A Bluestone; Abul K Abbas
Journal:  J Exp Med       Date:  2005-11-14       Impact factor: 14.307

10.  Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation.

Authors:  Petra Hoffmann; Joerg Ermann; Matthias Edinger; C Garrison Fathman; Samuel Strober
Journal:  J Exp Med       Date:  2002-08-05       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.